The HERA study is a clinical trial for the investigational drug, RG-012. HERA is a Phase II study designed to evaluate the safety and effectiveness of RG-012 compared to placebo in participants with Alport syndrome.
In the HERA study, approximately 40 male participants with a diagnosis of Alport syndrome will be assigned to receive the investigational drug, RG-012 or placebo. The study treatment will be assigned randomly (like flipping a coin):
Neither the participant nor the doctor will know what study treatment has been assigned.
Travel and lodging assistance is available as well as in-home visits.
You may be qualified for this study if you:
To locate your nearest study center, please use the site locator. The study team will contact you to review the study requirements and discuss whether you may be eligible to participate.